Skip to content
Peptigraph home
Shop Peptides50% off*

How Orforglipron Works: Mechanism and Pharmacology

How Orforglipron works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingOral small-molecule GLP-1 agonistUpdated
Class
Oral small-molecule GLP-1 agonist
FDA status
Approved (Foundayo, Apr 2026)
1 Apr 2026
Routes studied
oral; oral and intravenous
Half-life
approximately 29 to 49 hours
oral, in people · FDA label (Foundayo)

How long it acts

Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.

Orforglipron half-life by route
RouteHalf-lifeMeasured inSource
oralapproximately 29 to 49 hoursPeopleFDA label (Foundayo)
oral48.1 to 67.5 hours (day 28, 2-24 mg, healthy adults)PeopleDiabetes, obesity & metabolism 2023, PMID 37344954
oral29 to 49 hours (week 12, type 2 diabetes)PeopleDiabetes, obesity & metabolism 2023, PMID 37264711
As labelledapproximately 29 to 49 hours (oral)PeopleFDA label (Foundayo)

Full detail, including drug-testing windows, is on the Orforglipron half-life page.

Mechanism per the label

The Foundayo label says it is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.[1]

It describes GLP-1 as a physiological regulator of appetite and caloric intake.[1]

In animal studies, orforglipron reached and activated neurons in brain regions that regulate appetite and food intake.[1]

Not a peptide

The phase 2 obesity paper calls it a nonpeptide GLP-1 receptor agonist given once daily by mouth.[4]

Why once daily

The first-in-human paper concluded its long half-life of 25 to 68 hours allows once-daily oral dosing without water and food restrictions.[2]

The label says steady-state exposure is reached after approximately 1 week of once-daily use.[1]

Related peptides

Orforglipron vs TirzepatideGLP-1 / GIP dual agonistOrforglipron vs SemaglutideGLP-1 agonistOrforglipron vs RetatrutideGLP-1 / GIP / glucagon triple agonist

Common questions

How long does Orforglipron act in the body?

The half-life values we found are approximately 29 to 49 hours (oral); 48.1 to 67.5 hours (day 28, 2-24 mg, healthy adults) (oral). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.

How does orforglipron work?

It activates the human GLP-1 receptor, which regulates appetite and food intake.[1]

More on Orforglipron

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  2. 2Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
  3. 3Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
  4. 4Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026

Found an error? Report a correction.